Loading company…
Structure Therapeutics develops small-molecule medicines for chronic diseases, focusing on GPCR targets.
Founded in 2016, Structure Therapeutics, formerly ShouTi, develops medicines for chronic cardiovascular, metabolic and pulmonary diseases. Its platform uses AI, machine learning and other methods to design orally available small molecules targeting G-protein coupled receptors. In February 2023, it raised USD 161.1 million in a Nasdaq IPO at USD 15 per share under ticker GPCR.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in